Don’t let the high cost of brand single-tablet HIV regimens disrupt your treatment. We help eligible patients access Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
The Genvoya Prescription Assistance Program is a manufacturer-sponsored initiative that provides Genvoya at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for HIV treatment patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, HIV provider coordination, prior-authorization documentation, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and annual re-certification.
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$3,800.00 | Save ~$3,730/mo |
| CVS Pharmacy | ~$3,900.00 | Save ~$3,830/mo |
| Walmart | ~$3,500.00 | Save ~$3,430/mo |
| Costco | ~$3,450.00 | Save ~$3,380/mo |
| Kroger | ~$3,500.00 | Save ~$3,430/mo |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
The Patient Assistance Program is free to apply for and provides Genvoya at no medication cost if approved. Our $69.95/month service covers full advocacy. With Biktarvy and dolutegravir-based regimens now generally preferred by HIV guidelines, your provider may have already considered alternatives — we can help you and your provider determine the best path.
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Genvoya:
Still $3,400–$3,900 per month even with the best discount
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Genvoya assistance.
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Genvoya (EVG/c/FTC/TAF) is a once-daily, single-tablet, four-drug HIV-1 regimen combining the integrase strand transfer inhibitor (INSTI) elvitegravir, the pharmacokinetic booster cobicistat, and the NRTI backbone of emtricitabine and tenofovir alafenamide.
How Genvoya Works:
Genvoya is a four-drug combination that inhibits HIV replication by targeting both the integrase and reverse transcriptase enzymes. Elvitegravir prevents viral DNA from merging with the host genome, while emtricitabine and tenofovir alafenamide (TAF) block the copying of viral RNA. The inclusion of cobicistat acts as a booster to increase elvitegravir levels, while the TAF component ensures high effectiveness with reduced exposure to the kidneys and bones.
Form and use:
This medication is administered as a single tablet taken orally once per day and must be consumed with food. Because it contains cobicistat, which inhibits the CYP3A enzyme to boost drug levels, it carries a high potential for drug interactions. Consequently, it is essential for healthcare providers to review all other medications a patient is taking to ensure safety.
Generic availability:
As of 2026, there is no generic version of Genvoya available in the United States. Many patients have transitioned to newer options like Biktarvy or dolutegravir-based regimens, which are often preferred because they do not require a boosting agent. These modern alternatives typically offer a smaller pill burden and significantly fewer drug-to-drug interactions.
Warnings:
A boxed warning highlights the risk of severe HBV exacerbation upon discontinuation, requiring HBV testing for all patients before starting the drug. Genvoya is also associated with potential renal impairment and rare but serious conditions like lactic acidosis or severe liver enlargement. Due to the cobicistat component, significant drug interactions remain a primary safety concern for those on this regimen.
Genvoya costs approximately $3,400–$3,900 per 30-day supply. Through AffordMyPrescriptions, qualifying patients receive Genvoya at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Both are once-daily INSTI-based single-tablet regimens. Genvoya uses elvitegravir boosted with cobicistat (a CYP3A inhibitor) — meaning more drug interactions. Biktarvy uses bictegravir, an unboosted INSTI with fewer interactions. Both contain FTC/TAF. HIV guidelines now generally prefer Biktarvy or dolutegravir-based regimens for new starts. Many patients on Genvoya have switched to Biktarvy for the simpler interaction profile.
Elvitegravir absorption is increased by food. Taking Genvoya with food (any meal — light or heavy) ensures adequate elvitegravir exposure. Skipping food can reduce drug levels and risk virologic failure.
Yes — many. Cobicistat is a strong CYP3A inhibitor and inhibits other transporters too. This can raise levels of statins, certain antiarrhythmics, certain antifungals, certain anticonvulsants, and many other medications. Some combinations are contraindicated. Always tell every prescriber and pharmacist that you take Genvoya, and review all OTC products and supplements.
Yes. Medicare Part D beneficiaries can typically qualify, especially if you face specialty-tier copays. State ADAP programs may also coordinate with Medicare for HIV-treatment patients.
Tell your prescriber. Genvoya contains FTC and TAF, which are active against HBV — but if Genvoya is ever stopped without other anti-HBV therapy, severe acute HBV flares can occur. HBV testing is required before starting, and you should not stop Genvoya without your HIV provider’s guidance and HBV monitoring.
If denied, we explore alternatives — switching to Biktarvy (often available through its own PAP), state ADAP, the manufacturer’s copay program for commercially insured patients, or independent foundations. If we cannot find a path, you won’t be charged our service fee.
If you are struggling with the high cost of Genvoya, our team may be able to help you access assistance programs designed to make brand single-tablet HIV regimens affordable. Check your eligibility today.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.